Cellistic is a cell therapy process development and manufacturing company launched in April 2022, specializing in scaling human induced pluripotent stem cell (iPSC) technology. Their focus and expertise in iPSC generation and differentiation protocol development make the company a strategic partner for cell therapy developers to establish novel advanced therapies. Their team has decades of experience pursuing and supporting iPSC innovation, has completed over 60 projects, and has created cell lines derived from 35 sources.
Visit Company Website
